New high-strength nicotine patch

Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy (NRT) options.

Treatment with the patch, available in 10mg, 15mg and 25mg strengths, is started in most smokers at 25mg per day, a higher dose than that achieved with any other NRT patches currently on the market in the UK.

The 12-week step-down programme recommends that one 25mg patch (releasing 25mg nicotine over 16 hours) be applied daily for eight weeks (Step 1) followed by one 15mg patch applied daily for two weeks (Step 2) then one 10mg patch for the last two weeks (Step 3). Light smokers (those who smoke less than 10 cigarettes per day) are recommended to start at Step 2 (15mg) for eight weeks and reduce the dose to 10mg for the last four weeks.

Research shows that abstinence during the first week of a quit attempt is an important predictor of long-term success. The results of a European multicentre trial (n=3,575) show that Nicorette Invisipatch 25mg enabled 50 per cent of smokers who were abstinent during week one to remain smoke-free at week 12. In addition, in the first week of treatment Nicorette Invisipatch 25mg has been shown to significantly reduce adverse effects of nicotine withdrawal on mood by 79 per cent and 47 per cent compared with placebo and the 15mg patch, respectively. Nicorette Invisipatch has been shown to be 44 per cent more effective at 12 weeks than the previous Nicorette patch programme and is well tolerated.

Nicorette Invisipatch is semi-transparent and is smaller dose for dose than the previous Nicorette patch.

View Nicorette drug record

Further information: McNeil Products


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases